Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$14.09
+0.2%		$14.79
$12.96
▼
$20.90
$297.62M0.8151,486 shs36,563 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.18
-2.5%		$1.04
$0.56
▼
$2.98
$122.01M1.526.58 million shs5.00 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%+0.14%+3.60%-2.36%-11.10%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%+8.26%+15.69%-12.59%-36.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$14.09
+0.2%		$14.79
$12.96
▼
$20.90
$297.62M0.8151,486 shs36,563 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.18
-2.5%		$1.04
$0.56
▼
$2.98
$122.01M1.526.58 million shs5.00 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%+0.14%+3.60%-2.36%-11.10%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%+8.26%+15.69%-12.59%-36.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.00-7.74% Downside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.75
Moderate Buy$3.17168.36% Upside

Current Analyst Ratings Breakdown

Latest AMRN and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight$13.00
8/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Positive$1.80 ➝ $3.00
8/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/3/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$4.00
7/29/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/1/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/16/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$213.65M1.39$0.36 per share39.03$21.00 per share0.67
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K2,033.53N/AN/A$0.04 per share29.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.99N/AN/AN/A-14.56%-0.20%-0.14%11/4/2026 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.91N/AN/AN/AN/A-669.94%-73.97%11/10/2026 (Estimated)

Latest AMRN and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2167-$0.07+$0.1467-$0.07$0.53 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.67
2.67
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.00
1.00

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36021.12 million20.23 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
320103.40 million101.64 millionOptionable

Recent News About These Companies

Inovio Pharmaceuticals, Inc. $INO Shares Sold by Two Seas Capital LP
August 23 at 6:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-inovio-pharmaceuticals-inc-ino-shares-sold-by-two-seas-capital-lp-2026-08-23/
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from Brokerages
August 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30967971
HC Wainwright Issues Optimistic Forecast for INO Earnings
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965091
Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimate-for-inovio-pharmaceuticals-raised-by-analyst-2026-08-17/
Equities Analysts Set Expectations for INO Q4 Earnings
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963282
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/inovio-pharmaceuticals-nasdaqino-upgraded-to-hold-at-wall-street-zen-2026-08-15/
HC Wainwright Issues Negative Estimate for INO Earnings
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-estimate-for-ino-earnings-2026-08-14/
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/inovio-pharmaceuticals-nasdaqino-upgraded-to-strong-buy-at-zacks-research-2026-08-14/
Inovio (INO) Q2 2026 Earnings Call Transcript
August 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/INO/pressreleases/3817961/inovio-ino-q2-2026-earnings-call-transcript/
INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299646-inovio-pharmaceuticals-inc-inovio-reports-second-quarter-2026-financial-results-and-recent-business-highlights-008.htm
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
August 13, 2026  |  app.moby.coA
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/inovio-pharmaceuticals-inc-ino-q2-050345655.html
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/inovio-pharmaceuticals-inc-nasdaqino-receives-consensus-recommendation-of-hold-from-analysts-2026-08-13/
Inovio Pharmaceuticals Q2 Earnings Call Highlights
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/inovio-pharmaceuticals-q2-earnings-call-highlights-2026-08-12/
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935661-inovio-pharmaceuticals-inc-ino-q2-2026-earnings-call-transcript
Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/inovio-pharmaceuticals-nasdaqino-releases-quarterly-earnings-results-beats-expectations-by-015-eps-2026-08-12/
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/inovio-reports-second-quarter-2026-200500163.html
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/inovio-reports-second-quarter-2026-financial-results-and-recent-business-highlights-302849959.html
Bet on 5 Top-Ranked Stocks With Rising P/E
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2968617/bet-on-5-top-ranked-stocks-with-rising-p-e?cid=cs-stocknewsapi-ft-analyst_blog|rw-2968617
Inovio Pharmaceuticals (INO) Projected to Release Earnings on Wednesday
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/inovio-pharmaceuticals-ino-projected-to-release-earnings-on-wednesday-2026-08-05/
INOVIO to Report Second Quarter Financial Results on August 12, 2026
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/inovio-report-second-quarter-financial-200500098.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$14.09 +0.03 (+0.21%)
As of 08/21/2026 04:00 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.18 -0.03 (-2.48%)
As of 08/21/2026 04:00 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas